Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 264-269

  Francini, Filippo ^a   Pascucci, Alessandra ^a   Bargagli, Gianluca ^a   Francini, Edoardo ^a   Conca, Raffaele ^a   Miano, Salvatora Tindara ^a   Martellucci, Ignazio ^a   Migali, Cristina ^a   Gotti, Giuseppe ^a   Fiaschi, Anna Ida ^a   Cozzolino, Annunziata ^a   Petrioli, Roberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bone markers; Bone metastases; Breast cancer; Ibandronate; NSCLC; Prostate cancer; Zoledronate

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; IBANDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PAIN; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PATHOLOGIC FRACTURE; PATIENT ASSESSMENT; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ALKALINE PHOSPHATASE; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; BONE RESORPTION; CARCINOMA, NON-SMALL-CELL LUNG; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052720817     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0179-x     Document Type: Article

References (36)

1. Clezardin P, Teti A (2007) Bone metastasis. Clin Exp Metastasis 24:599-608.
2. Coleman RE, Purohit OP, Vinholes JJ et al (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80(Suppl 8):1686-1690. (Pubitemid 27444042)
3. Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469-488. (Pubitemid 37522661)
4. Cameron D, Fallon M, Diel i (2006) Ibandronate: its role in metastatic breast cancer. Oncologist 11(Suppl 1):27-33.
5. Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567. (Pubitemid 32112871)
6. Berenson JR, Rosen LS, Howell A et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200.
7. Heidenreich A, Elert A, Hofmann R (2002) Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostate Dis 5:231-235.
8. Body JJ, Diel IJ, Lichinitser MR et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399-1405. (Pubitemid 37185286)
9. Body JJ, Diel IJ, Lichinitzer M et al (2004) Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo- controlled phase III studies. Br J Cancer 90:1133-1137. (Pubitemid 38496803)
10. Francini G, Gonnelli S, Petrioli R et al (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591-598.
11. Coleman RE (2002) The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521-2533. (Pubitemid 34478064)
12. Brown JE, Thomson CS, Ellis SP et al (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89:2031-2037. (Pubitemid 38030899)
13. Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935. (Pubitemid 46223998)
14. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69.
15. Hannon RA, Eastell R (2006) Bone markers and current laboratory assays. Cancer Treat Rev 32(Suppl 1):7-14.
16. Hamaoka T, Madewell JE, Podoloff DA et al (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942-2953. (Pubitemid 41079914)
17. Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277-299.
18. De Benedittis G, Massei R, Nobili R et al (1988) The Italian Pain Questionnaire. Pain 33:53-62.
19. McCormack A, Hunter-Smith D, Piotrowski ZH et al (1992) Analgesic use in home hospice cancer patients. J Fam Pract 34:160-164.
20. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:216.
21. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381. (Pubitemid 16163075)
22. Lipton A (2008) Emerging role of bisphosphonates in the clinicantitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(Suppl 1):S25-S30.
23. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel. Ann Oncol 19:420-432.
24. Francini G, Petrioli R, Gonnelli S et al (2001) Urinary calcium excretion in the monitoring of bone metastases. Cancer 92:1468-1474. (Pubitemid 32947831)
25. Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type i collagen is useful for monitoring therapeutic response in nonsmall cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484-488.
26. Hirsh V, Major PP, Lipton A et al (2008) Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228-236. (Pubitemid 351654321)
27. Panãres RL, Garcia AA (2007) Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:433-445. (Pubitemid 46681799)
28. Smith MR (2006) Markers of bone metabolism in prostate cancer. Cancer Treat Rev 32(Suppl 1):23-26.
29. Lein M, Miller K, Wirth M et al (2009) Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Prostate 69:624-632.
30. Body JJ, Lichinitser M, Tjulandin S et al (2007) Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 18:1165-1171. (Pubitemid 47244361)
31. Brown JE, McCloskey EV, Dewar JA et al (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease. Calcif Tissue Int 81:341-351. (Pubitemid 350077201)
32. Briesacher BA, Andrade SE, Yood RA et al (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882-887. (Pubitemid 47593009)
33. Cramer JA, Gold DT, Silverman SL et al (2007) A systemic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031. (Pubitemid 47019996)
34. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818.
35. Hochberg MC, Silverman SL, Barr CE et al (2010) The utility of changes in serum levels of C-terminal telopeptide of type i collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom 13:181-189.
36. Tripathy D, Body JJ, Bergström B (2004) Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 26:1947-1959. (Pubitemid 40353606)